Late Breaking KidneyIntelX data show care impact

LONDON and NEW YORK, 16 April 2025 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine company with lead testing service kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in chronic kidney disease, notes the publication of an abstract entitled: "Impact of KidneyIntelX on Targeted Use of SGLT2i".

The Late Breaking study describes how researchers assessed the increase in prescription rates of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in response to KidneyIntelX testing, and for the first time, compared this increase to a control population who did not receive the KidneyIntelX test but were treated in the same health system over the same time period and were eligible for testing.

James McCullough, CEO of Renalytix, commented: "This new data continues to demonstrate the powerful utility of KidneyIntelX to drive changes in care for patients who need it most. It is notable that almost 70% of patients in this study are treated at primary care and demonstrates that in the absence of clear and early risk assessment, the opportunity to change the course of disease can be lost resulting in catastrophic outcomes for patients."

The authors report that risk assessment for DKD progression with KidneyIntelX not only resulted in increased use of SGLT2i but importantly, that increase was targeted to those patients at moderate or high-risk of progression. Conversely, new use of SGLT2i in the control group was not optimised for kidney health with the lowest increase observed in patients subsequently identified as high risk.

The presented data also highlights how patients identified as low risk by KidneyIntelX do not appear to benefit from SGLT2i treatment for kidney health protection while patients in moderate and high-risk groups benefit most from early and targeted intervention.

The lead author is Joji Tokita, MD, from the Icahn School of Medicine Mount Sinai, New York, and was presented at the National Kidney Foundation Spring Clinical Meetings in Boston, MA on 10-13 April 2025. The full abstract and data can be viewed here: